Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: A randomized, placebo-controlled trial

Obstetrics and Gynecology

Volumn 89, Issue 4, 1997, Pages 615-622

  Redmond, Geoffrey P ^a   Olson, William H ^b   Lippman, Joel S ^b   Kafrissen, Michael E ^b   Jones, Terry M ^b   Jorizzo, Joseph L ^b  

^a Five Commerce Park   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; NORGESTIMATE; PLACEBO; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIPHASIC CONTRACEPTIVE AGENT;

ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SELF EVALUATION; SKIN DEFECT; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ACNE VULGARIS; ADOLESCENT; ADULT; DRUG THERAPY, COMBINATION; ESTRADIOL CONGENERS; ETHINYL ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NORGESTREL; PROSPECTIVE STUDIES;

EID: 0031127746     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(97)00059-8     Document Type: Article

References (27)

1. 1. Lucky AW. Hormonal correlates of acne and hirsutism. Am J Med 1995;98 Suppl 1A:89S-94S.
2. 2. Pochi PE. Hormonal aspects of acne. J Int Postgrad Med 1991;4:7-10.
3. 3. Lever L, Marks R. Current views on the aetiology, pathogenesis and treatment of acne vulgaris. Drugs 1990;39:681-92.
4. 4. Darley CR, Moore JW, Besser GM, Munro DD, Edwards CRW, Rees LH, et al. Androgen status in women with late onset or persistent acne vulgaris. Clin Exp Dermatol 1984;9:28-35.
5. 5. Mango D, Ricci S, Manna P, Miggiano GAD, Serra GB. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris. Contraception 1996;53:163-70.
6. 6. Wishart J. An open study of triphasil and Diane 50 in the treatment of acne. Australas J Dermatol 1991;32:51-4.
7. 7. Lemay A, Dewailly S, Grenier R, Huard J. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,1-norgestrel. J Clin Endocrinol Metab 1990;71:8-14.
8. 8. Erkkola R, Hirvonen E, Luikku J, Lumme R, Mannikko H, Aydinlik S. Ovulation inhibitors containing cyproterone acetate or desogestrel in the treatment of hyperandrogenic symptoms. Acta Obstet Gynecol Scand 1990;69:61-5.
9. 9. Aydinlik S, Lachnit-Fixson U, Lehnert J. Reduced estrogen ovulation inhibitor in acne therapy: Double-blind study comparing Diane-35 to Diane. Fortschr Med 1986;104:547-50.
10. 10. Miller JA, Wojnarowska FT, Dowd PM, Ashton RE, O'Brien TJ, Griffiths WAD, et al. Anti-androgen treatment in women with acne: A controlled trial. Br J Dermatol 1986;114:705-16.
11. 11. Carlborg L. Cyproterone acetate versus levonorgestrel combined with ethinyl estradiol in the treatment of acne: Results of a multicenter study. Acta Obstet Gynecol Scand Suppl 1986;134:29-32.
12. 12. Janaud A, Rouffy J, Upmalis D, Dain M. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. Acta Obstet Gynecol Scand Suppl 1992;156:33-8.
13. 13. London RS, Chapdelaine A, Upmalis D, Olson W, Smith J. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet Gynecol Scand Suppl 1992;156:9-14.
14. 14. Becker H. Supportive European data on a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand Suppl 1990; 152:33-9.
15. 15. Chapdelaine A, Desmarais J, Derman RJ. Clinical evidence of the minimal androgenic activity of norgestimate. Int J Fertil 1989;34: 347-52.
16. 16. Plewig G, Kligman A. Acne and rosacea. 2nd ed. New York: Springer-Verlag, 1993.
17. 17. Philips A. The selectivity of a new progestin. Acta Obstet Gynecol Scand Suppl 1990;152:21-4.
18. 18. Andolsek K. Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent. Acta Obstet Gynecol Scand 1992;71:22-6.
19. 19. Burkman R, Kafrissen M, Olson W, Osterman J. Lipid and carbohydrate effects of a new triphasic oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand 1992;71:5-8.
20. 20. Marynick SP, Chakmakjian ZH, McCaffree DL, Herndon JH. Androgen excess in cystic acne. N Engl J Med 1983;308:981-6.
21. 21. Lawrence DM, Katz M, Robinson TWE, Newman MC, McGarrigle HHG, Shaw M, et al. Reduced sex hormone binding globulin and derived free testosterone levels in women with severe acne. Clin Endocrinol (Oxf) 1981;15:87-91.
22. 22. Lucky AW, McGuire J, Rosenfield RL, Lucky PA, Rich BH. Plasma androgens in women with acne vulgaris. J Invest Dermatol 1983; 81:70-4.
23. 23. Schiavone FE, Rietschel RL, Sgoutas D, Harris R. Elevated free testosterone levels in women with acne. Arch Dermatol 1983;119: 799-802.
24. 24. Gammon WR, Meyer C, Lantis S, Shenefelt P, Reizer G, Cripps DJ. Comparative efficacy of oral erythromycin versus oral tetracycline in the treatment of acne vulgaris. J Am Acad Dermatol 1986;14:183-6.
25. 25. Henderson TA, Olson WH, Leach AD. A single-blind, randomized comparison of erythromycin pledgets and clindamycin lotion in the treatment of mild to moderate facial acne vulgaris. Adv Ther 1995;12:172-7.
26. 26. Mandy SH, Vicik GJ, Thorne EG. 0.01% tretinoin gel: A safe and effective topical treatment of inflammatory acne. Adv Ther 1984; 1:404-9.
27. 27. Shalita AR, Chalker DK, Ellis CN, Parish LC, Smith JG. A multi-center, double-blind, controlled study of the combination of erythromycin/benzoyl peroxide, erythromycin alone, and benzoyl peroxide alone in the treatment of acne vulgaris. Cutis 1992;49:1-4.